Skip to main content
SpringerLink
Log in

Le cancer du pancréas et la génétique

Pancreatic cancer and genetics

  • Mise au Point / Update
  • Published:
Oncologie

Résumé

Le cancer du pancréas est un cancer relativement rare, mais au pronostic très sombre. Le rapport incidence/décès est de 0,99. Le taux de survie à cinq ans, tous stades confondus, est l’un des plus bas, il est d’environ 5 % en Europe comme aux États-Unis. Donc, c’est très préoccupant en matière de santé publique. Le dépistage du cancer pancréatique permettant un diagnostic précoce de la maladie, et donc augmentant les chances de traitement curatif, n’existe pas. Le cancer pancréatique est dans la plupart des cas sporadique. Néanmoins, il existe des formes familiales de cette affection tumorale qui sont responsables d’une proportion importante, plus de 10 % des cas leur sont imputables. Dans cette revue, on s’est focalisé sur la génétique du cancer pancréatique, particulièrement le cancer pancréatique survenant dans un contexte familial.

Abstract

Pancreatic cancer, although relatively rare, does have a very poor prognosis. The ratio of incidence to deaths is 0.99. The survival rate at five years from all stages is one of the lowest, at around 5% in both Europe and the USA. It is therefore a serious public health issue. Screening for pancreatic cancer, which would enable an early diagnosis to be made and thus increase the chances of being cured, does not exist. In the majority of cases, pancreatic cancer is sporadic. However, there are familial forms of this disease, which are responsible for a significant proportion of cases, with more than 10% of cases being attributable to this type. In this review, focus is on the genetics of pancreatic cancer, in particular pancreatic cancer occurring within the same family.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Sant M, Allemani C, Santaquilani M, et al. (2009) Eurocare-4, survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 45: 931–91

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, et al. (2009) Cancer statistics. CA Cancer J Clin 59: 225–49

    Article  PubMed  Google Scholar 

  3. Mitry E, Artru P, Rougier P (2004) Épidémiologie, présentation et classification du cancer du pancréas exocrine. In: Lledo G, ed. Le cancer du pancréas exocrine. John Libbey Eurotext, Paris, pp. 1–10

    Google Scholar 

  4. De Martel C, Franceschi S, Partensky C (2010) Épidémiologie du cancer du pancréas. In: Delpero JR, Paye F, Bachellier P (eds) Cancer du pancréas. Arnette, Paris, pp. 12–26

    Google Scholar 

  5. Turrini O, Cano C, Legoffic A, et al. (2009) Les altérations génétiques dans les lésions précancéreuses pancréatiques et leurs implications en clinique. Gastroenterol Clin Biol 33: 1–9

    Article  Google Scholar 

  6. Torrisani J, Bournet B, Cordelier P (2008) Nouvelles cibles moléculaires dans le cancer du pancréas. Bull Cancer 95: 503–12

    CAS  PubMed  Google Scholar 

  7. Balian A (2011) Hépato-gastro-entérologie. Elsevier Masson SAS, Paris

    Google Scholar 

  8. Jones S, Zhang X, Parsons DW, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–6

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Brune K, Hong SM, Li A, et al. (2008) Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 17: 3536–42

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Hruban RH, Adsay NV (2009) Molecular classification of neoplasms of the pancreas. Hum Pathol 40: 612–23

    Article  CAS  PubMed  Google Scholar 

  11. Lambert R (2009) Épidémiologie du cancer du pancréas dans le monde. Cancero Dig 1: 199–204

    Article  Google Scholar 

  12. Hong SM, Park JY, Hruban RH, Goggins M (2011) Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 135: 716–27

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Shi C, Hruban RH, Klein AP (2009) Familial Pancreatic Cancer. Arch Pathol Lab Med 133: 365–74

    PubMed  Google Scholar 

  14. Giardiello FM, Offerhaus GJ, Lee DH, et al. (1993) Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 34: 1394–6

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Elkharwily A, Gottlieb K (2008) The pancreas in familial adenomatous polyposis. JOP 9: 9–18

    PubMed  Google Scholar 

  16. Maire F, Hammel P, Terris B, et al. (2002) Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 51: 446–9

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Abraham SC, Wu TT, Klimstra DS, et al. (2001) Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome. Am J Pathol 159: 1619–27

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Birch JM, Alston RD, McNally RJ, et al. (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20: 4621–28

    Article  CAS  PubMed  Google Scholar 

  19. Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 189: 1–7

    Article  CAS  PubMed  Google Scholar 

  20. Lefrou L, Godart B, Muret AD, et al. (2006) Germline tp53 neomutation in a patient with Li-Fraumeni syndrome and pancreatic adenocarcinoma. Gastroenterol Clin Biol 30: 484

    Article  PubMed  Google Scholar 

  21. Su GH, Hruban RH, Bansal RK, et al. (1999) Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 154: 1835–40

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Giardiello FM, Brensinger JD, Tersmette AC, et al. (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119: 1447–53

    Article  CAS  PubMed  Google Scholar 

  23. Lim W, Olschwang S, Keller JJ, et al. (2004) Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 126: 1788–94

    Article  CAS  PubMed  Google Scholar 

  24. Matthaei H, Schulick RD, Hruban RH, Maitra A (2011) Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol 8: 141–50

    Article  PubMed Central  PubMed  Google Scholar 

  25. Canto MI, Goggins M, Hruban RH, et al. (2006) Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study. Clinical gastroenterology and hepatology 4: 766–781

    Article  PubMed  Google Scholar 

  26. Riker AI, Hagmaier R (2011) The Familial Atypical Multiple Mole Melanoma (FAMMM)-Pancreatic Carcinoma (PC) Syndrome. In: C. Neal-Ellis (ed) Inherited Cancer Syndromes: Current Clinical Management, 2de ed., Springer, pp 135–44

    Chapter  Google Scholar 

  27. Hruban RH, Canto MI, Goggins M, et al. (2010) Update on familial pancreatic cancer. Adv Surg 44: 293–311

    Article  PubMed Central  PubMed  Google Scholar 

  28. Goldstein AM, Chidambaram A, Halpern A, et al. (2002) Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res 12: 51–5

    Article  CAS  PubMed  Google Scholar 

  29. Habbe N, Langer P, Sina-Frey M, Bartsch DK (2006) Familial pancreatic cancer syndromes. Endocrinol Metab Clin North Am 35: 417–30

    Article  CAS  PubMed  Google Scholar 

  30. Whelan AJ, Bartsch D, Goodfellow PJ (1995) Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-supressor gene. N Engl J Med 333: 975–7

    Article  CAS  PubMed  Google Scholar 

  31. Vasen HF, Gruis NA, Frants RR, et al. (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16. Int J Cancer 87: 809–11

    Article  CAS  PubMed  Google Scholar 

  32. Rulyak SJ, Brentnall TA, Lynch HT, Austin MA (2003) Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 98: 798–804

    Article  CAS  PubMed  Google Scholar 

  33. Goldstein AM (2004) Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 23: 630

    Article  PubMed  Google Scholar 

  34. Molven A, Grimstvedt MB, Steine SJ, et al. (2005) A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 44: 10–8

    Article  CAS  PubMed  Google Scholar 

  35. No authors listed (1999) The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–6

    Article  Google Scholar 

  36. Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14: 185–7

    Article  CAS  PubMed  Google Scholar 

  37. Couch FJ, Johnson MR, Rabe KG, et al. (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16: 342–6

    Article  CAS  PubMed  Google Scholar 

  38. Goggins M, Schutte M, Lu J, et al. (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56: 5360–4

    CAS  PubMed  Google Scholar 

  39. Hahn SA, Greenhalf B, Ellis I, et al. (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95: 214–21

    Article  CAS  PubMed  Google Scholar 

  40. Murphy KM, Brune KA, Griffin C, et al. (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 62(13): 3789–93

    CAS  PubMed  Google Scholar 

  41. White K, Held KR, Weber BH (2001) A BRCA2 germ-line mutation in familial pancreatic carcinoma. Int J Cancer 91: 742–4

    Article  CAS  PubMed  Google Scholar 

  42. Martin ST, Matsubayashi H, Rogers CD, et al. (2005) Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24: 3652–6

    Article  CAS  PubMed  Google Scholar 

  43. Aparicio A, Dominguez-Tinajero S, Mitry E (2006) Tumeurs endocrines digestives et pancréatiques. In: Rougier P, Mitry E, Dominguez S, Taieb J (eds) Les cancers digestifs. Springer, France, pp. 219–40

    Chapter  Google Scholar 

  44. Libé R, Chanson P (2007) Les tumeurs endocrines du pancréas lors de la néoplasie endocrinienne multiple type 1(NEM1): actualités sur les facteurs pronostiques, l’imagerie et le traitement. Ann Endocrinol 68: 1–8

    Article  Google Scholar 

  45. Le Bodic L, Bignon JD, Raguénès O, et al. (1996) The hereditary pancreatitis gene maps to long arm of chromosome 7. Hum Mol Genet 5: 549–54

    Article  PubMed  Google Scholar 

  46. Lamoril J, Bouizegarène P, Phung L (2003) Pancréatites héréditaires. Immunoanal Biol Spec 18: 174–84

    Google Scholar 

  47. Charnley RM (2003) Hereditary pancreatitis. World J Gastroenterol 9: 1–4

    PubMed  Google Scholar 

  48. Lowenfels AB, Maisonneuve P, Di-Magno EP, et al. (1997) Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89: 442–6

    Article  CAS  PubMed  Google Scholar 

  49. Rebours V, Lévy P, Mosnier JF, et al. (2010) Pathology analysis reveals that dysplastic pancreatic ductal lesions are frequent in patients with hereditary pancreatitis. Clin Gastroenterol Hepatol 8: 206–12

    Article  PubMed  Google Scholar 

  50. Rebours V (2009) États précancéreux du pancréas. Post’U FMCHE, pp. 93–103

    Google Scholar 

  51. Klein AP, Brune KA, Petersen GM, et al. (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64: 2634–8

    Article  CAS  PubMed  Google Scholar 

  52. Slater EP, Langer P, Niemczyk E, et al. (2010) PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78: 490–4

    Article  CAS  PubMed  Google Scholar 

  53. Jones S, Hruban RH, Kamiyama M, et al. (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324: 217

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Hamel N, Tischkowitz M, Foulkes WD (2008) PALB2/FANCN, acteur dans la prédisposition au cancer du sein? Med Sci 24: 120–1

    Google Scholar 

  55. Gilgenkrantz S (2007) Cancer familial du pancréas et gène palladin: un nouveau regard sur le processus cancéreux. Med Sci 23: 232–4

    Google Scholar 

  56. Earl J, Yan L, Vitone LJ, et al. (2006) Evaluation of the 4q32–34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 15: 1948–55

    Article  CAS  PubMed  Google Scholar 

  57. Klein AP, Borges M, Griffith M, et al. (2009) Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 18: 1328–30

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Salaria SN, Illei P, Sharma R, et al. (2007) Palladin is overexpressed in the nonneoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol Ther 6: 324–8

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Slater E, Amrillaeva V, Fendrich V, et al. (2007) Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med 4: 164

    Article  Google Scholar 

  60. Zogopoulous G, Rothenmund H, Eppel A, et al. (2007) The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet 121: 635–7

    Article  Google Scholar 

  61. Greenhalf W, Neoptolemos J (2010) Genetic susceptibility and high risk groups of pancreatic cancer. In: Neoptolemos J, Urrutia R, Abbruzzese J, Büchler M (eds) Pancreatic Cancer. Springer science, New York, pp. 565–600

    Chapter  Google Scholar 

  62. Wolpin BM, Chan AT, Hartge P, et al. (2009) ABO Blood Group and the Risk of Pancreatic Cancer. J Natl Cancer Inst 101: 424–31

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Wolpin BM, Kraft P, Gross M, et al. (2010) Pancreatic cancer risk and ABO Blood Group Alleles: results from the Pancreatic Cancer Cohort Consortium. Cancer Res 70: 1015–23

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Yonezawa S, Higashi M, Yamada N, et al. (2010) Significance of mucin expression in pancreatobiliary neoplasms. Hepatobiliary Pancreat Sci 17: 108–24

    Article  Google Scholar 

  65. Andrianifahanana M, Moniaux N, Schmied BM, et al. (2001) Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 7: 4033–40

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département de biochimie, faculté des sciences, université Badji-Mokhtar-Annaba, Annaba, Algérie

    S. Boumendjel

Authors
  1. S. Boumendjel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Boumendjel.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boumendjel, S. Le cancer du pancréas et la génétique. Oncologie 17, 321–329 (2015). https://doi.org/10.1007/s10269-015-2527-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-015-2527-y

Mots clés

Keywords

Search

Navigation